Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 9, 2013, Pages

  Kirouac, D C ^a   Onsum, M D ^b  

^a MERRIMACK PHARMACEUTICALS   (United States)

^b Silver Creek Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; RITUXIMAB;

APOPTOSIS; CANCER RESISTANCE; COMPUTER MODEL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MATHEMATICAL MODEL; MELANOMA; MONTE CARLO METHOD; NONHUMAN; ONCOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SIMULATION;

EID: 84885162221     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.38     Document Type: Review

References (56)

1. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 2009.
2. Scannell, J.W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 2012.
3. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 2004.
4. Vicini, P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin. Pharmacol. Ther. 88, 126-129 2010.
5. Graaf, P.H., van der & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics PKPD in drug discovery and development. Pharm. Res. 28, 1460-1464 2011.
6. Gutenkunst, R.N., Waterfall, J.J., Casey, F.P., Brown, K.S., Myers, C.R. & Sethna, J.P. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput. Biol. 3, 1871-1878 2007. (Pubitemid 350043403)
7. Sorger, P.K. et al. Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms An NIH White Paper by the QSP Workshop Group-October, 2011. NIH White paper 2011.
8. Reimand, J. & Bader, G.D. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol. Syst. Biol. 9, 637 2013.
9. Iyengar, R., Zhao, S., Chung, S.W., Mager, D.E. & Gallo, J.M. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126ps7 2012.
10. Mager, D.E. & Jusko, W.J. Development of translational pharmacokineticpharmacodynamic models. Clin. Pharmacol. Ther. 83, 909-912 2008.
11. Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. & Sorger, P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 2006. (Pubitemid 44266307)
12. Yap, T.A., Gerlinger, M., Futreal, P.A., Pusztai, L. & Swanton, C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4, 127ps10 2012.
13. Aldridge, B.B., Burke, J.M., Lauffenburger, D.A. & Sorger, P.K. Physicochemical modelling of cell signalling pathways. Nat. Cell Biol. 8, 1195-1203 2006. (Pubitemid 44660581)
14. Huang, C.Y. & Ferrell, J.E. Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U.S.A. 93, 10078-10083 1996. (Pubitemid 26314577)
15. Bhalla, U.S. & Iyengar, R. Emergent properties of networks of biological signaling pathways. Science 283, 381-387 1999.
16. Schoeberl, B. et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2, ra31 2009.
17. McDonagh, C.F. et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 11, 582-593 2012.
18. Fitzgerald, J. & Lugovskoy, A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 3, 299-309 2011.
19. Harms, B.D., Kearns, J.D., Su, S.V., Kohli, N., Nielsen, U.B. & Schoeberl, B. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Meth. Enzymol. 502, 67-87 2012.
20. Kirouac, D.C., Saez-Rodriguez, J., Swantek, J., Burke, J.M., Lauffenburger, D.A. & Sorger, P.K. Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. BMC Syst. Biol. 6, 29 2012.
21. Morris, M.K., Saez-Rodriguez, J., Sorger, P.K. & Lauffenburger, D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 49, 3216-3224 2010.
22. Morris, M.K., Saez-Rodriguez, J., Clarke, D.C., Sorger, P.K. & Lauffenburger, D.A. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Comput. Biol. 7, e1001099 2011.
23. Wittmann, D.M., Krumsiek, J., Saez-Rodriguez, J., Lauffenburger, D.A., Klamt, S. & Theis, F.J. Transforming Boolean models to continuous models: methodology and application to T-cell receptor signaling. BMC Syst. Biol. 3, 98 2009.
24. Hartwell, L.H., Hopfield, J.J., Leibler, S. & Murray, A.W. From molecular to modular cell biology. Nature 402, C47-C52 1999.
25. The Cancer Genome Atlas. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 2008.
26. TCGA Network et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 2012.
27. Stephens, P.J. et al.; Oslo Breast Cancer Consortium OSBREAC. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 2012.
28. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36, 1090-1098 2004. (Pubitemid 41184471)
29. Liu, Y.Y., Slotine, J.J. & Barabási, A.L. Observability of complex systems. Proc. Natl. Acad. Sci. U.S.A. 110, 2460-2465 2013.
30. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817 2011.
31. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 2012.
32. Sos, M.L. et al. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 18351-18356 2009.
33. Cirit, M., Wang, C.C. & Haugh, J.M. Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase ERK signaling network. J. Biol. Chem. 285, 36736-36744 2010.
34. Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 2011.
35. Duncan, J.S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 2012.
36. Nik-Zainal, S. et al.; Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell 149, 994-1007 2012.
37. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 2013.
38. Irish, J.M. et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228 2004. (Pubitemid 38962577)
39. Cohen, A.A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511-1516 2008.
40. Diaz, L.A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 2012.
41. Miller-Jensen, K., Janes, K.A., Brugge, J.S. & Lauffenburger, D.A. Common effector processing mediates cell-specific responses to stimuli. Nature 448, 604-608 2007. (Pubitemid 47206933)
42. Lee, M.J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 2012.
43. Mould, D.R. & Upton, R.N. Basic concepts in population modeling, simulation, and modelbased drug development. CPT: Pharma. Syst. Pharmacol. 1, e6 2012.
44. Claret, L. et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J. Clin. Oncol. 27, 4103-4108 2009.
45. Wang, Y. et al. Elucidation of relationship between tumor size and survival in non-smallcell lung cancer patients can aid early decision making in clinical drug development. Clin. Pharmacol. Ther. 86, 167-174 2009.
46. Gaudet, S., Spencer, S.L., Chen, W.W. & Sorger, P.K. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Comput. Biol. 8, e1002482 2012.
47. Kauffman, S.A. Metabolic stability and epigenesis in randomly constructed genetic nets. J. Theor. Biol. 22, 437-467 1969.
48. Saez-Rodriguez, J., Alexopoulos, L.G. & Stolovitzky, G. Setting the standards for signal transduction research. Sci. Signal. 4, pe10 2011.
49. Janes, K.A. & Yaffe, M.B. Data-driven modelling of signal-transduction networks. Nat. Rev. Mol. Cell Biol. 7, 820-828 2006. (Pubitemid 44627475)
50. Kirouac, D. et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 2013.
51. Wong, H. et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 18, 3090-3099 2012.
52. Harrold, J.M., Straubinger, R.M. & Mager, D.E. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res. 72, 1632-1641 2012.
53. Wang, S., Guo, P., Wang, X., Zhou, Q. & Gallo, J.M. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol. Cancer Ther. 7, 407-417 2008. (Pubitemid 351302534)
54. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217-228 2013.
55. Kirouac, D.C., Madlambayan, G.J., Yu, M., Sykes, E.A., Ito, C. & Zandstra, P.W. Cell-cell interaction networks regulate blood stem and progenitor cell fate. Mol. Syst. Biol. 5, 293 2009.
56. Kirouac, D.C. et al. Dynamic interaction networks in a hierarchically organized tissue. Mol. Syst. Biol. 6, 417 2010.